DeepSight Technology is set to unveil the ‘NeedleVue LiteCart Ultrasound System’ at the forthcoming Radiological Society of North America (RSNA) annual meeting.
At this event, the company expects to secure interest from clinicians willing to partner on clinical research for assessing the device.
Go deeper with GlobalData
NeedleVue is a new ultrasound-guided needle technology that aims to improve precision and confidence during medical procedures. It is engineered to provide real-time visualisation of needles, guidewires, and catheters without the need for radiation or complex calibration.
It is set to simplify and democratise interventional procedures by embedding tiny sensors at the tip of various instruments. The device is set to simplify procedures, allowing clinicians to perform with increased confidence and precision.
This self-calibrating technology requires no advanced setup and is compatible with free-hand procedural workflows.
Its non-electrical and inert design is unaffected by temperature and magnetic fields, making it suitable for abdominal procedures such as biopsies, and potentially across various medical specialities.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe system operates effectively even with contrast agents, providing comprehensive visibility within and outside the imaging plane.
DeepSight’s NeedleVue marks a significant shift in needle guidance technology by providing real-time, precision needle tracking that is both portable and user-friendly, addressing the needs of healthcare providers for operational efficacy and optimised patient outcomes.
These features claim a paradigm shift in needle guidance technology, combining operational efficacy with optimised patient outcomes.
DeepSight Technology CEO and co-founder Nader Sadrzadeh said: “The potential applications for NeedleVue technology, including integrated solutions, are endless. NeedleVue aims to overcome existing limitations and represents the future of ultrasound-guided interventional procedures.”
The NeedleVue LiteCart Ultrasound system has not yet received authorisation from the US Food and Drug Administration and is currently unavailable for sale or use.
